title: Effects of the inhalation of the m3 receptor antagonist bencycloquidium bromide in a mouse cigarette smoke-induced airway inflammation model.
abstract: Bencycloquidium bromide (BCQB), a novel M3 receptor antagonist, alleviates airway hyperresponsiveness, inflammation, and airway remodeling in a murine model of asthma. The aim of this study was to investigate the anti-inflammatory activity of inhaled BCQB in a cigarette smoke (CS)-induced model of acute lung inflammation. Mice exposed to CS developed chronic obstructive pulmonary disease (COPD). Inhalation of BCQB suppressed the accumulation of neutrophils and macrophages in airways and lung and also inhibited the CS-induced increases in mRNA levels of keratinocyte-derived chemokine, monocyte chemotactic protein-1, tumor necrosis factor-alpha, and interleukin-1β in lung and protein expression levels in bronchoalveolar lavage fluid. Moreover, BCQB (300 μg/ml) inhibited the CS-induced changes in superoxide dismutase and myeloperoxidase activities in the lungs. Our study suggests that BCQB might be a potential therapy for inflammation in CS-induced pulmonary diseases, including COPD.
authors.affiliation: Department of Pharmacy, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
authors.forename: Shui-Juan
authors.initials: SJ
authors.lastname: Zhang
authors.affiliation: Department of Pharmacology, Zhejiang University School of Medicine, Hangzhou, China, 310058.
authors.forename: Jun-Xia
authors.initials: JX
authors.lastname: Jiang
authors.affiliation: Department of Pharmacy, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
authors.forename: Qian-Qian
authors.initials: QQ
authors.lastname: Ren
authors.affiliation: Department of Pharmacology, Zhejiang University School of Medicine, Hangzhou, China, 310058.|Department of Medicine, Laboratory Animal Center of Zhejiang University, Hangzhou, China, 310058.
authors.forename: Qiang-Min
authors.initials: QM
authors.lastname: Xie
authors.affiliation: Department of Pharmacy, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
authors.forename: Yao-Kang
authors.initials: YK
authors.lastname: Xiong
mesh_terms: D000280:Administration, Inhalation; D000818:Animals; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000008:administration & dosage*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005260:Female; D008168:Lung / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D051379:Mice; D008813:Mice, Inbred ICR; D011014:Pneumonia / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D043587:Receptor, Muscarinic M3 / Q000037:antagonists & inhibitors*; D012906:Smoke / Q000009:adverse effects*; D012907:Smoking / Q000009:adverse effects / Q000378:metabolism / Q000473:pathology; D014026:Nicotiana / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D019086:Bridged Bicyclo Compounds, Heterocyclic; D043587:Receptor, Muscarinic M3; D012906:Smoke; C518439:bencycloquidium bromide
keywords: airway inflammation; bencycloquidium bromide; cigarette smoke; drug delivery; muscarinic receptor antagonist